Business
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma – – Up to 87% of newly diagnosed pancreatic cancer patients are considered inoperable at diagnosis and face a dismal prognosis, with limited benefit from existing therapies – – This pilot study is a key part of A
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U8Q3xNkSuAPosRUnHeWZmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –","length":133,"tagName":"p"},{"type":"text","content":"– Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma –","length":165,"tagName":"p"},{"type":"text","content":"– Up to 87% of newly diagnosed pancreatic cancer patients are considered inoperable at diagnosis and face a dismal prognosis, with limited benefit from existing therapies –","length":177,"tagName":"p"},{"type":"text","content":"– This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs –","length":152,"tagName":"p"},{"type":"text","content":"JERUSALEM, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that the first patient has been treated in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma.","length":570,"tagName":"p"},{"type":"image","alt":"PR - Pancreas PR IMPACT patient 1 v3","displaySize":"","headline":null,"caption":"PR - Pancreas PR IMPACT patient 1 v3","className":"","disableSlideshowImg":false,"size":{"original":{"width":1080,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/dbd99cf9ef2374e3bebc4babe8c5cb08"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DWc_cqXLx_I...